Old Web
English
Sign In
Acemap
>
authorDetail
>
Anna Stefanska
Anna Stefanska
Novartis
Secukinumab
Medicine
Internal medicine
Ankylosing spondylitis
outcome measures
3
Papers
21
Citations
0.00
KQI
Citation Trend
Filter By
Interval:
1900~2024
1900
2024
Author
Papers (3)
Sort By
Default
Most Recent
Most Early
Most Citation
No data
Journal
Conference
Others
Secukinumab 150/300 mg Provides Sustained Improvements in the Signs and Symptoms of Active Ankylosing Spondylitis: 3‐Year Results from the Phase 3 MEASURE 3 Study
2020
Karel Pavelka
Alan J. Kivitz
Eva Dokoupilova
Ricardo Blanco
Marco Maradiaga
Hasan Tahir
Yi Wang
Brian Porter
Anna Stefanska
Hanno Richards
Susanne Rohrer
Show All
Source
Cite
Save
Citations (11)
5-year efficacy and safety of secukinumab in patients with ankylosing spondylitis: end-of-study results from the phase 3 MEASURE 2 trial
2020
Helena Marzo-Ortega
Joachim Sieper
Alan J. Kivitz
Ricardo Blanco
Martin Cohen
Karel Pavelka
Eumorphia-Maria Delicha
Anna Stefanska
Hanno Richards
Susanne Rohrer
Show All
Source
Cite
Save
Citations (9)
FRI0379 LONG-TERM EVALUATION OF SECUKINUMAB 150 MG IN ANKYLOSING SPONDYLITIS: 5-YEAR END-OF-STUDY EFFICACY AND SAFETY RESULTS FROM A PHASE 3 TRIAL
2019
Annals of the Rheumatic Diseases
Helena Marzo-Ortega
Joachim Sieper
Alan J. Kivitz
Ricardo Blanco
Martin Cohen
Karel Pavelka
Eumorphia-Maria Delicha
Anna Stefanska
Hanno Richards
Susanne Rohrer
Show All
Source
Cite
Save
Citations (1)
1